What adjuvant HER2‑targeted therapy regimen is recommended for a 70‑year‑old woman with hypertension, dyslipidaemia, Karnofsky performance status 80, estrogen‑ and progesterone‑receptor negative, HER2‑positive T1c N0 breast cancer after mastectomy?

Adjuvant HER2-Targeted Therapy Recommendation

For this 70-year-old woman with T1c N0 HER2-positive, HR-negative breast cancer, I recommend adjuvant chemotherapy with trastuzumab for 1 year, with the preferred regimen being docetaxel-carboplatin-trastuzumab (TCH) given her cardiovascular comorbidities. 1

Rationale for HER2-Targeted Therapy

The 2024 NCCN guidelines explicitly recommend adjuvant chemotherapy with trastuzumab (Category 1) for tumors >1 cm in HER2-positive disease 1. T1c tumors (>1.0-2.0 cm) clearly meet this threshold. The 2018 ASCO guidelines similarly state that trastuzumab plus chemotherapy is recommended for patients with HER2-positive, node-negative breast cancer >1 cm 2.

Optimal Chemotherapy Regimen Selection

Given this patient's hypertension and dyslipidemia, TCH (docetaxel-carboplatin-trastuzumab for 6 cycles) is the preferred regimen over anthracycline-containing options. The rationale is compelling:

• Cardiotoxicity profile: The BCIRG-006 trial demonstrated significantly lower rates of congestive heart failure and cardiac dysfunction with TCH compared to anthracycline-trastuzumab combinations (P<0.001) 3
• Equivalent efficacy: At 65-month follow-up, TCH showed no significant difference in disease-free survival or overall survival compared to AC-T plus trastuzumab 3
• Additional safety: Only 1 case of acute leukemia occurred in the TCH arm versus 7 in anthracycline-containing arms 3

The 2018 ASCO guidelines specifically state: "Less cardiotoxicity is seen with docetaxel-carboplatin-trastuzumab than with doxorubicin-cyclophosphamide → docetaxel-trastuzumab, and docetaxel-carboplatin-trastuzumab is recommended for patients at higher risk for cardiotoxicity" 2.

Age and Comorbidity Considerations

Age 70 with cardiovascular comorbidities places this patient at higher cardiac risk, making anthracycline avoidance particularly important. A systematic review of elderly patients (>60 years) receiving adjuvant trastuzumab showed a 47% relative risk reduction in disease-free survival, but noted that "uncertainty about cardiac safety in the elderly is a major concern" with a pooled cardiac event rate of 5% 4. The International Society of Geriatric Oncology position paper emphasizes that cardiovascular comorbidity requires careful consideration in older patients, though fit patients should receive standard HER2-targeted therapy 5.

With a Karnofsky score of 80, this patient is considered fit enough for standard therapy, but the cardiovascular comorbidities mandate choosing the least cardiotoxic effective regimen.

Alternative Regimen (If TCH Not Tolerated)

If the patient cannot tolerate platinum-based therapy or taxanes, weekly paclitaxel plus trastuzumab for 12 weeks is an acceptable alternative for T1c N0 disease 1. The NCCN guidelines note this regimen showed 10-year invasive disease-free survival of 91.3% with only 0.5% incidence of heart failure, though this is listed as preferred specifically for lower-risk T1N0M0 disease 1.

Duration and Monitoring

Trastuzumab should be administered for 1 year total with regular cardiac function assessments throughout treatment 2, 1. The guidelines emphasize that trastuzumab should be administered concurrently (not sequentially) with non-anthracycline chemotherapy regimens 2.

Critical Pitfalls to Avoid

• Do not administer trastuzumab concurrently with anthracyclines due to increased cardiotoxicity risk 2
• Do not omit trastuzumab despite age or comorbidities—the survival benefit is substantial (47% relative risk reduction) 4
• Do not use sequential rather than concurrent trastuzumab with non-anthracycline regimens, as concurrent administration is preferred 2
• Do not skip baseline and interval cardiac monitoring—essential given her cardiovascular risk factors